Last $0.72 USD
Change Today -0.02 / -2.70%
Volume 2.7K
ECTE On Other Exchanges
As of 10:51 AM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

echo therapeutics inc (ECTE) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/26/13 - $4.91
52 Week Low
09/24/14 - $0.39
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ECHO THERAPEUTICS INC (ECTE)

Related News

No related news articles were found.

echo therapeutics inc (ECTE) Related Businessweek News

No Related Businessweek News Found

echo therapeutics inc (ECTE) Details

Echo Therapeutics, Inc. is engaged in the development of transdermal skin permeation and diagnostic medical devices. It is developing Symphony CGM system (Symphony), a needle-free wireless continuous glucose monitoring system for use in hospital critical care units; and Symphony SkinPrep system, a component of its Symphony for enhanced skin permeation that enables extraction of analytes, such as glucose. The company is also engaged in the development Durhalieve, an AzoneTS formulation of triamcinolone acetonide that has completed Phase III clinical trials for the treatment of corticosteroid-responsive dermatoses. It has a licensing agreement with Ferndale Pharma Group, Inc. to develop, market, sell, and distribute Prelude SkinPrep system for skin preparation prior to the application of topical anesthetics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community; a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell Symphony for continuous glucose monitoring for use by medical facilities and/or individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd. The company was founded in 1989 and is headquartered in Philadelphia, Pennsylvania.

28 Employees
Last Reported Date: 03/28/14
Founded in 1989

echo therapeutics inc (ECTE) Top Compensated Officers

Acting Chief Executive Officer, Chief Complia...
Total Annual Compensation: $220.0K
Compensation as of Fiscal Year 2013.

echo therapeutics inc (ECTE) Key Developments

Echo Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Echo Therapeutics, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, total revenue was $0.02 million against $0.02 million last year. Loss from operations was $2.9 million against $4.9 million last year. Net loss for the third quarter of 2014 was $5.5 million, or $0.43 per basic and diluted share as compared to $5.2 million, or $0.49 per basic and diluted share, for the third quarter of 2013. For the nine months, total revenue was $0.06 million against $0.07 million last year. Loss from operations was $9.5 million against $16.5 million last year. Net loss was $12.0 million, or $0.99 per basic and diluted share as compared to $15.6 million, or $2.06 per basic and diluted share last year.

Echo Therapeutics, Inc. announced delayed 10-Q filing

On 11/14/2014, Echo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Echo Therapeutics Not In-Compliance With Nasdaq Listing Rules

On November 6, 2014, Echo Therapeutics, Inc. received a letter from the Listing Qualifications Department of the NASDAQ Stock Market (“Nasdaq”) informing the Company that because the closing bid price for the Company's common stock listed on Nasdaq was below $1.00 for 30 consecutive business days, the Company does not comply with the minimum closing bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2). The letter further provides that, under the Nasdaq rules, the Company has a 180-day compliance period, or until May 5, 2015, to regain compliance with Nasdaq's listing requirements by having the closing bid price of its common stock be at least $1.00 for at least 10 consecutive trading days. In the event that the Company does not regain compliance by May 5, 2015, the Company may be granted an additional 180-day compliance period, provided that the Company (i) meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and (ii) provides written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the Nasdaq staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, the Nasdaq staff will notify the Company that its common stock will be subject to delisting. In the event that the Company does not regain compliance within the requisite time period, it would have the right to appeal a delisting determination. Failure to maintain listing on the Nasdaq Capital Market may have a material adverse effect on the price and/or liquidity of the Company’s common stock. During this process, shares of the Company's common stock will continue to trade on the Nasdaq Capital Market.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ECTE:US $0.72 USD -0.02

ECTE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $44.07 USD -0.09
Bayer AG €117.55 EUR -0.35
Johnson & Johnson $106.97 USD +0.27
Roche Holding AG SFr.286.20 CHF +0.40
View Industry Companies

Industry Analysis


Industry Average

Valuation ECTE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 537.4x
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 449.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ECHO THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at